

25th June 2024

- | | |
|---|--|
| <p>(1) BSE Limited
Listing Department,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001</p> <p>Scrip Code: 500087</p> | <p>(2) National Stock Exchange of India Limited
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051</p> <p>Scrip Code: CIPLA EQ</p> |
| <p>(3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg</p> | |

Dear Sir/Madam,

Sub: USFDA inspection at Company's manufacturing facility in Patalganga, Maharashtra, India

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and further to our intimation dated 4th April 2024, regarding the routine current Good Manufacturing Practices (cGMP) inspection at our Patalganga manufacturing facility, we wish to inform you that the United States Food and Drug Administration (USFDA) vide communication dated Tuesday, 25th June 2024 (12:37 AM IST) has classified the above referred inspection as Voluntary Action Indicated ("VAI").

Please take the above information on record.

Yours faithfully,
For Cipla Limited

Rajendra Chopra
Company Secretary

Prepared by: Mandar Kurghode